Objective To investigate the rate of serious bacterial, viral or opportunistic infection in
patients with rheumatoid arthritis (RA) starting tocilizumab (TCZ) versus tumour necrosis …

Objectives To examine the rate of incident malignancies excluding non-melanoma skin
cancer (NMSC) in patients with rheumatoid arthritis (RA) newly treated with tocilizumab …

Objectives. To investigate the occurrence and risk factors for infections in RA patients treated
with tocilizumab. Methods. A cohort of all RA patients (n= 112) starting tocilizumab therapy …

Objective Subcutaneous (SC) and intravenous formulations of tocilizumab (TCZ) are
available for the treatment of patients with rheumatoid arthritis (RA), based on the efficacy …

Objective To evaluate the safety and efficacy of tocilizumab in clinical practice in patients
with rheumatoid arthritis (RA) with inadequate responses (IR) to disease-modifying …

Objective While tocilizumab (TCZ) is known to increase low‐density lipoprotein (LDL)
cholesterol levels, it is unclear whether TCZ increases cardiovascular risk in patients with …

Introduction The objective of this study was to directly compare the safety of tocilizumab
(TCZ) and TNF inhibitors (TNFIs) in rheumatoid arthritis (RA) patients in clinical practice …

Objective. To assess the risk of adverse events (AEs) in patients with RA treated with
tocilizumab, an IL-6 receptor antibody, in published randomized controlled trials (RCTs) …

Introduction The efficacy and safety of tocilizumab in patients with rheumatoid arthritis have
been evaluated in a comprehensive phase 3 program. Patients from these randomized trials …

Objectives To examine the effectiveness of tocilizumab (TCZ) with and without synthetic
disease-modifying antirheumatic drugs (sDMARDs) in a large observational study. Methods …